NL-OMON41388
Recruiting
Not Applicable
TApering strategies in Rheumatoid Arthritis remission induced by anti-TNF&classic DMARDs. Should we taper the classic DMARD or anti-TNF first? - TARA
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- rheumatism
- Sponsor
- Erasmus MC, Universitair Medisch Centrum Rotterdam
- Enrollment
- 355
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •RA patients, aged \>17 years, treated with DMARDs\&etanercept,adalimumab,certolizumab or golimumab, DAS \<\= 2\.4 and swollen joint count \<\=1 for two consecutive time points (3 months)
Exclusion Criteria
- •Not being able to understand, speak and write in Dutch.
- •Being diagnosed with a psychiatric or personality disorder.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Treatment strategies for Rheumatoid Arthritis (BeSt - BehandelStrategieën in Reumatoïde Artritis)Rheumatoid arthritisMusculoskeletal DiseasesArthropathiesISRCTN32675862eiden University Medical Centre (LUMC) (Netherlands)508
Completed
Not Applicable
BeSt, BehandelStrategieën in Reumatoïde Artritis.NL-OMON24149Dutch College of Health Insurance Companies508
Completed
Not Applicable
Active management of rheumatoid arthritis (RA)ISRCTN78142229Record Provided by the NHSTCT Register - 2004 Update - Department of Health (UK)100
Recruiting
Not Applicable
TrEatment Targets in Rheumatoid Arthritis: a randomized multi-centre, treat to target strategy trial: TETRA studyjoint inflammationrheumatoid arthritis1000381610023213NL-OMON53234Sint Maartenskliniek340
Completed
Not Applicable
Supplemental treatment of rheumatoid arthritis with natural milk antibodies against enteromicrobes and their toxinsJPRN-UMIN000003128Asama Chemical Co. Ltd.,40